(ARGX) argenx - Ratings and Ratios
FcgRn-Blocker, MusK-Agonist, Il6-Antibody, FcRn-Inhibitor, Galectin10-Antibody
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 38.2% |
| Value at Risk 5%th | 51.2% |
| Relative Tail Risk | -18.51% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.16 |
| Alpha | 35.65 |
| CAGR/Max DD | 0.84 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.464 |
| Beta | 0.442 |
| Beta Downside | 0.551 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.20% |
| Mean DD | 11.05% |
| Median DD | 7.77% |
Description: ARGX argenx December 04, 2025
argenx SE (NASDAQ: ARGX) is a commercial-stage biotech headquartered in Amsterdam that focuses on FcRn-targeted antibodies for autoimmune disorders. Its marketed products, VYGART (efgartigimod) and VYGART HYTRULO, are approved in the U.S. and EU for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company’s pipeline expands beyond FcRn inhibition to include MuSK agonists (ARGX-119), IL-6 blockade (ARGX-109), and novel targets such as Galectin-10 (ARGX-118), with multiple collaborations spanning AbbVie, Zai Lab and Chugai to accelerate development across North America, Europe and Asia.
Key recent metrics: as of Q2 2024, argenx reported $210 million in total revenue, a 45 % YoY increase driven by VYGART sales, and held $1.3 billion in cash and marketable securities, giving it ~18 months of runway at current burn. The biotech sector’s average forward-price-to-sales multiple remains around 12×, while argenx trades at roughly 9× forward sales, suggesting a relative discount that may reflect execution risk in later-stage trials. A macro driver is the growing demand for targeted immunotherapies, with global autoimmune disease therapeutics projected to exceed $150 billion by 2028, supporting long-term market expansion for FcRn-based agents.
For a deeper quantitative assessment of argenx’s valuation and risk profile, you may find the analytical tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.62b TTM) > 0 and > 6% of Revenue (6% = 252.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 12.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 113.7% (prev 142.9%; Δ -29.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 479.8m <= Net Income 1.62b (YES >=105%, WARN >=100%) |
| Net Debt (-2.04b) to EBITDA (844.1m) ratio: -2.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.7m) change vs 12m ago 10.53% (target <= -2.0% for YES) |
| Gross Margin 77.07% (prev 90.95%; Δ -13.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.36% (prev 54.91%; Δ 15.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 156.2 (EBITDA TTM 844.1m / Interest Expense TTM 3.96m) >= 6 (WARN >= 3) |
Altman Z'' 3.50
| (A) 0.67 = (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b |
| (B) -0.16 = Retained Earnings (Balance) -1.16b / Total Assets 7.18b |
| (C) 0.10 = EBIT TTM 618.3m / Avg Total Assets 5.99b |
| (D) -0.99 = Book Value of Equity -1.07b / Total Liabilities 1.08b |
| Total Rating: 3.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.16
| 1. Piotroski 5.0pt |
| 2. FCF Yield 0.89% |
| 3. FCF Margin 11.24% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -2.42 |
| 6. ROIC - WACC (= 1.88)% |
| 7. RoE 32.57% |
| 8. Rev. Trend 45.08% |
| 9. EPS Trend 93.67% |
What is the price of ARGX shares?
Over the past week, the price has changed by +0.65%, over one month by +3.56%, over three months by +17.29% and over the past year by +47.42%.
Is ARGX a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 978.6 | 8.6% |
| Analysts Target Price | 978.6 | 8.6% |
| ValueRay Target Price | 1156.9 | 28.4% |
ARGX Fundamental Data Overview December 06, 2025
P/E Trailing = 39.1273
P/E Forward = 31.1526
P/S = 15.4871
P/B = 9.3105
P/EG = 1.0109
Beta = -0.111
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 53.16b USD (57.04b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
FCF Yield = 0.89% (FCF TTM 473.5m / Enterprise Value 53.16b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 7.41 (Enterprise Value 53.16b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.64% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 7.64% (E(57.04b)/V(57.09b) * Re(7.64%) + D(43.2m)/V(57.09b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 6.42%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈473.5m ; Y1≈310.9m ; Y5≈142.2m
Fair Price DCF = 45.39 (DCF Value 2.79b / Shares Outstanding 61.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 93.67 | EPS CAGR: 200.3% | SUE: 0.46 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 173.1% | SUE: 1.33 | # QB: 2
EPS next Quarter (2026-03-31): EPS=5.92 | Chg30d=+0.241 | Revisions Net=+4 | Analysts=9
EPS next Year (2026-12-31): EPS=25.41 | Chg30d=+0.924 | Revisions Net=+14 | Growth EPS=+69.3% | Growth Revenue=+38.0%
Additional Sources for ARGX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle